Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:CMPciliatine)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteUnits(range)
ST001788 AN002900 β-Adrenergic regulation of metabolism in macrophages (part-IV) Macrophages Human Monash University Intensity
ST001188 AN001980 P. falciparum infected erythrocytes Cultured cells Plasmodium falciparum Malaria University of Melbourne ion count
ST002477 AN004046 Neutrophil metabolomics in COVID-19 Neutrophils Human COVID-19 UT Southwestern Medical Center MS reading
ST002371 AN003866 High-resolution metabolomics analysis of NLRP3 inflammasome activated macrophages Macrophages Mouse Inflammation Wake Forest School of Medicine peak area
ST001611 AN002645 Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment Muscle Mouse Cancer North Carolina State University Peak area
ST001611 AN002645 Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment Sarcoma Mouse Cancer North Carolina State University Peak area
ST003340 AN005474 Effect of feeding and the mTORC1 activity on metabolism in Caenorhabditis elegans Worm Roundworm Hiroshima University peak areas
ST002792 AN004543 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University peak height
ST002926 AN004799 Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression Blood Plasmodium falciparum Malaria Monash University peak height
ST003144 AN005160 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University peak height
ST000403 AN000642 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000539 AN000818 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST000546 AN000833 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences, Monash University Peak height
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University Peak height
ST001276 AN002117 Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds Cultured cells Trypanosoma brucei Sleeping sickness Monash University Peak height
ST003160 AN005184 New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites Plasmodium cells Plasmodium falciparum Malaria Monash University Peak height
ST003179 AN005221 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University Peak height
ST001201 AN001999 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001201 AN001999 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001202 AN002001 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001202 AN002001 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001205 AN002007 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University Peak intensity
ST001205 AN002007 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University Peak intensity
ST001547 AN002577 β-Adrenergic regulation of metabolism in macrophages Macrophages Human Monash University Peak intensity
ST002106 AN003445 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) Blood Plasmodium falciparum Malaria Monash University relative intensity
ST002107 AN003446 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University relative intensity
ST002108 AN003449 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University relative intensity
ST002309 AN003772 Targeting malaria parasites with novel derivatives of azithromycin Blood Plasmodium falciparum Malaria Monash University relative intensity
ST001175 AN001951 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University Signal Intensity
ST001315 AN002190 Retargeting azithromycin-like compounds as antimalarials with dual modality Blood Plasmodium falciparum Malaria Monash University Signal Intensity
  logo